Loading company…
ID 405328863 · FY 2019–2024 · 6 years
კომპანიის ძირითადი საქმიანობაა საბიუმო ვაჭრობა ფარმაცევტული საქონლით, კომპანიას მინიჭებული აქვს სპეციალური სავაჭრო კომპანიის სტატუსი.
Bars are revenue on the left axis; lines are EBITDA and net margin on the right.
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|
| Net Cash from Operating Activities | 519 | -731 | 189 | -196 | -62 | 551 | +1.2% |
| Net Cash used in Investing Activities | -0 | -206 | -11 | 62 | 0 | 0 | nmf |
| Free Cash Flow (OCF − Capex proxy) | 519 | -937 | 178 | -134 | -62 | 551 | +1.2% |
| Net Cash from Financing Activities | 92 | 356 | -17 | 11 | 22 | -40 | nmf |
| Net Change in Cash (before FX) | 611 | -581 | 162 | -122 | -40 | 511 | -3.5% |
| Net Change in Cash (incl. FX) | 611 | -581 | 162 | -122 | -40 | 511 | -3.5% |
| Cash at Beginning of Year | 0 | 611 | 30 | 191 | 69 | 29 | -53.2% |
| Cash at End of Year | 611 | 30 | 191 | 69 | 29 | 540 | -2.4% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Companies sharing this sub-sector, ranked by how close their latest revenue is to this one — not a curated comp set.
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).